Equities
Health CareHealth Care Equipment & Services
  • Price (EUR)155.12
  • Today's Change1.84 / 1.20%
  • Shares traded364.33k
  • 1 Year change+32.92%
  • Beta0.8288
Data delayed at least 15 minutes, as of Jul 23 2021 16:39 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

EssilorLuxottica SA, formerly known as Essilor International Compagnie Generale D Optique SA, is a France-based ophthalmic company. The Company designs, manufactures and markets a range of lenses, frames and sunglasses to improve and protect eyesight. It also develops and markets equipment for prescription laboratories and instruments, and services for eye care professionals. It operates through three segments: Lenses and Optical Instruments, which includes corrective lenses, optical instruments intended for opticians and optometrists; Equipment, which includes machines and consumables used by plants and prescription laboratories, and Sunglasses & Readers, which encompasses non-prescription reading glasses and non-prescription sunglasses. The Company operates under a number of brands, including Ray-Ban, Oakley and Varilux, among others. The Company operates in Europe, North America, Asia Pacific, the Middle East, Africa and Latin America.

  • Revenue in EUR (TTM)14.43bn
  • Net income in EUR85.00m
  • Incorporated1993
  • Employees144.51k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
EL:PAR since
announced
Transaction
value
Walman Optical CoAnnounced25 Mar 202125 Mar 2021Announced16.11%--
Data delayed at least 15 minutes, as of Jul 23 2021 16:39 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Smith & Nephew plc3.87bn380.09m15.96bn17.91k42.013.5518.624.120.370.373.774.380.4490.84483.59184,953.104.417.915.259.5769.3972.899.8213.701.7611.020.411446.96-11.25-0.3214-25.331.794.35-5.90
Carl Zeiss Meditec AG1.39bn159.08m16.47bn3.37k102.9610.65--11.861.791.7915.5717.280.64582.048.29421,848.607.447.948.949.9656.6255.4611.5210.173.397.480.118536.70-8.495.13-23.3914.4621.815.64
Sonova Holding AG2.40bn536.88m20.96bn14.51k38.388.0829.038.729.189.1841.1543.590.49982.546.34179,342.4011.2410.3314.6113.1072.2670.9322.4916.561.8529.990.348123.30-10.804.6631.9510.411.448.79
Straumann Holding AG1.32bn84.35m24.25bn7.02k290.9321.76136.8518.405.675.6789.5475.810.57741.764.24203,257.503.7413.464.6516.2572.2275.296.4718.552.477.610.365234.41-10.6712.29-70.225.2518.467.53
Coloplast A/S2.49bn578.73m29.85bn12.50k55.5734.4243.3112.0020.1720.1786.6932.571.292.815.801,488,694.0029.9131.5753.6054.5768.0467.8823.2622.680.647666.890.372989.513.375.928.3736.098.587.57
Koninklijke Philips NV19.20bn1.12bn37.40bn77.34k34.03--14.621.951.201.2720.82--------235,354.00--3.98--5.6943.8646.275.886.03--80.48----0.2723.060.927552.532.611.63
Sartorius Stedim Biotech SA2.39bn474.45m42.58bn8.75k89.8125.5270.5917.795.145.1425.9418.100.83292.219.01316,280.9016.7013.9321.7718.3053.5751.7120.0516.820.823335.500.264820.4232.5916.6552.6024.8424.6115.33
Siemens Healthineers AG15.02bn1.57bn61.81bn54.50k36.554.1825.534.121.501.5014.4113.100.50263.844.25278,166.705.326.647.0010.9838.5140.2210.5810.082.3053.880.032---0.39952.25-9.962.029.37--
EssilorLuxottica SA14.43bn85.00m68.52bn144.51k881.662.1029.914.750.17590.175932.8773.840.27512.976.4599,846.380.28412.820.32383.3657.8160.531.037.471.9110.640.266259.39-17.0316.53-92.11-35.4214.7314.97
Data as of Jul 23 2021. Currency figures normalised to EssilorLuxottica SA's reporting currency: Euro EUR

Institutional shareholders

10.77%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 20217.37m1.67%
Capital Research & Management Co. (World Investors)as of 31 Mar 20217.11m1.61%
Norges Bank Investment Managementas of 31 Dec 20206.62m1.50%
Capital Research & Management Co. (Global Investors)as of 31 Mar 20216.04m1.37%
BlackRock Fund Advisorsas of 08 Jul 20214.48m1.02%
Massachusetts Financial Services Co.as of 28 May 20213.91m0.88%
Amundi Asset Management SA (Investment Management)as of 31 Dec 20203.56m0.81%
Comgest SAas of 30 Apr 20212.93m0.66%
BlackRock Advisors (UK) Ltd.as of 08 Jul 20212.83m0.64%
TIAA-CREF Investment Management LLCas of 31 May 20212.72m0.62%
More ▼
Data from 31 Dec 2020 - 31 Mar 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.